ArticleClinical lung cancer2025
Outcomes and Toxicity following 3 or More Definitive Courses of Thoracic Radiation Therapy for Non-Small Cell Lung Cancer.
Article in Clinical lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeSalvage re-irradiation is increasingly utilized to manage non-small cell lung cancer (NSCLC) locoregional recurrence or new lung primaries in previously treated areas. There is sparse information on efficacy and toxicity profile. We report a large experience of patients treated with multiple courses of definitive radiation for new and recurrent NSCLC. METHODS AND MATERIALS: Medical records of patients who underwent ≥ 3 definitive thoracic radiation therapy (RT) courses for new or recurrent NSCLC at our cancer center from 2012 through 2021 were retrospectively reviewed following institutional review board approval. Toxicity was graded per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and outcomes were estimated using Kaplan-Meier.
resultsAmong 51 patients meeting inclusion criteria, there were 161 definitive thoracic RT courses (8 received 4 courses). Of these courses, 119 (74%) entailed SBRT for localized lesions; the remaining were conventional fractionation (half included concurrent chemotherapy). Seventeen patients (33%) received SBRT for every thoracic treatment course. There was overlap of treatment fields between separate courses for 38 patients (75%). Following last thoracic RT, median overall survival (OS) was 2.9 years (range, 1.5-4.4) and progression-free survival (PFS) was 14-months (range, 8.5-19). Three-year estimated OS (±standard error) was 81% (± 10%) for patients who received SBRT for every course and 32% (± 9%) among those treated with mixed modality. Overall Grade 3 toxicity incidence was 6%, no Grade 4 or 5 events.
conclusionDefinitive thoracic radiation can be a safe and effective local control modality (despite multiple prior treatments) and should be considered when planning multidisciplinary salvage therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.